Determining the Role of CDK12 in Driving Prostate Cancer Initiation, Progression, and Responses to Therapeutics
Abstract
CDK12 is inactivated in 6.9% of metastatic castration-resistant prostate cancer; however, the functional and clinical significance of this event is not clear. In this grant we are investigating the role and mechanisms of Cdk12 in prostate cancer using tissue specific gene targeting in mice. During the reporting period we performed all the studies that were originally planned for the first year. We generated mice with prostate-specific inactivation of Cdk12 with and without overexpression of MYC and presently expanding and analyzing these mutant mice.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2020
- Accession Number
- AD1106987
Entities
People
- Valeri Vasioukhin
Organizations
- Fred Hutchinson Cancer Center